Biotechnology company Epistem has entered into an agreement with Veritas Corporation to exclusively market and distribute Epistem’s scientific research services in Japan.
Located in Manchester, Epistem’s contract research division provides specialised preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammatory bowel disease, wound healing and skincare.
Epistem have an established customer base in Western Europe and the U.S and the Veritas agreement will provide Epistem with a sales and marketing presence in Japan and the opportunity to extend its research services, and respond rapidly to market demand.
Epistem’s CEO Matthew Walls commented: “We are delighted to be working with Veritas. They have a strong scientific sales team and established distribution network. The Japanese drug development market provides us with an important opportunity for growth and the agreement with Veritas will allow us to develop closer links with existing Japanese customers.”
Sinsaku Iida, Veritas CEO said: ”It is our great pleasure to work with Epistem. Epistem’s Contract Research Division has a strong preclinical and scientific research service capability which will benefit Japanese pharmaceutical and personal care companies. Veritas’ sales network has the scientific experience necessary to introduce Epistem’s high quality services to potential Japanese customers and will make for more efficient marketing and easier access for Japanese customers to Epistem.“